Aurora Cannabis Inc. has entered into a definitive agreement with Organigram Global Inc. for the acquisition of all outstanding common shares of Aurora at a price of C$7.80 per share. This transaction represents a significant move in the medicinal cannabis sector, providing Aurora's shareholders with immediate value and the option to receive their consideration in cash, shares of Organigram, or a combination of both.

The acquisition, announced on November 3, 2026, comes at a time when the cannabis industry is witnessing heightened competition and consolidation. The deal values Aurora at approximately C$561 million and offers a 93% premium to Aurora's share price prior to the announcement of a hostile bid from Curaleaf Holdings, which was unanimously rejected by Aurora's board.

Background

Aurora Cannabis Inc., headquartered in Edmonton, Alberta, is a prominent player in the medicinal cannabis market, classified under the SIC code 2833 for Medicinal Chemicals & Botanical Products. The company trades on the Nasdaq under the ticker ACB. Its recent filings indicate a series of strategic moves, including amendments to its solicitation/recommendation statement.

What the Filing Says

The recent filing, an amendment to Schedule 14D-9F, outlines the details of the acquisition agreement with Organigram. It states, "The Transaction provides Aurora shareholders with compelling immediate value, meaningful choice in how they receive their consideration, and the opportunity for continued participation in the future growth and value creation of the combined company." This statement emphasizes the benefits of the merger for Aurora's shareholders.

Impact

This acquisition is expected to significantly impact both Aurora and Organigram. For Aurora, it means a strengthened position in the global cannabis market, enhanced operational capabilities, and a more substantial financial base. Organigram, already a leader in recreational cannabis, will benefit from Aurora's established international presence and medical cannabis expertise. The merger is poised to create a more competitive entity capable of meeting the growing global demand for cannabis products.

What's Next

The filing does not specify the next steps following this announcement, but it indicates that both companies' boards of directors have expressed unanimous support for the transaction. Shareholders will likely be called to vote on the acquisition in the coming weeks.